Molecular Profiles, a contract research services provider, has named Dr. Mike Fanfarillo as operations director and Dr. Robert Sherry as associate director in pharmaceutics. "We are delighted to announce these two new appointments as an expansion to our team", comments Dr. Nikin Patel, Molecular Profiles' chief executive officer. "Following on from the recent successful recruitment of a number of experienced scientists, both Mike's and Robert's extensive specialisms reinforce Molecular Profile's commitment to enhancing our in-house expertise and service offering."
As operations director, Dr. Fanfarillo is responsible for the management of research projects and the development of the technical team and services. He is also a study director on numerous patent-related projects. He has more than 20 years' experience in the pharmaceutical industry having worked for ICI/Zeneca Pharmaceuticals, Boots Healthcare International and Reckitt Benckiser Healthcare International. His expertise covers the range of preparative, analytical and characterization techniques used in the pharmaceutical development of medicinal products, from chromatography to spectroscopy. Dr. Fanfarillo also has extensive experience of writing and assembling Drug Product License applications, writing Pharmaceutical Expert Reports and assessment of API Drug Master Files from third-party manufacturers.
Dr. Sherry is an expert in a wide range of product dose forms. In his role as associate director in pharmaceutics, he will consult on a range of formulation issues facing pharmaceutical companies in the development of their products, including utilizing outputs from investigations to assert intellectual property rights for these clients. He is also responsible for directing technical studies to resolve complex formulation issues and for developing collaborations with academic and industrial experts. Dr. Sherry has more than 20 years of industrial experience at Boots Healthcare International covering a wide range of formulation types and product formats. He has particular experience of regulatory requirements for new license submissions, clinical trials manufacture and significant patent experience, with several formulation and process patents granted.
Magazine
